Avacta Group (LON:AVCT) Announces Quarterly Earnings Results

Avacta Group (LON:AVCT) posted its earnings results on Wednesday. The biotechnology company reported GBX (4.23) EPS for the quarter, Digital Look Earnings reports. Avacta Group had a negative net margin of 35,730.97% and a negative return on equity of 1,293.07%.

Avacta Group Stock Performance

Shares of AVCT stock opened at GBX 72 on Friday. The firm’s 50 day moving average price is GBX 69.74 and its 200-day moving average price is GBX 71.81. The company has a debt-to-equity ratio of 526.98, a quick ratio of 4.96 and a current ratio of 0.95. Avacta Group has a one year low of GBX 48 and a one year high of GBX 92. The firm has a market cap of £337.35 million, a P/E ratio of -7.45 and a beta of 1.12.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).